Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment Responses?

NCT02188758 is registered in ClinicalTrials.gov with Dartmouth-Hitchcock Medical Center as lead sponsor.

NCT NCT02188758
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02188758 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment Responses?
Lead sponsor
Dartmouth-Hitchcock Medical Center
Phase
Observational
Overall status
Completed
Start date
July 31, 2014
Completion date
January 31, 2018
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis